Table 2.
Demographic and Clinical Characteristics of Patients With COVID-19 by Diabetes Control Status
| Characteristics | All DMa | HbA1c control category (n=56,745) |
|||
|---|---|---|---|---|---|
| All with COVID-19 | <7% | 7%–9% | >9% | ||
| 656,049 | 84,726 | 24,900 | 19,930 | 11,915 | |
| Overall | 100% | 12.9 (12.7, 13.1) | 43.9 (43.3, 44.5) | 35.1 (34.5, 35.8) | 21 (20.3, 21.7) |
| Age, years | |||||
| 20–39 | 38.6 (38.5, 38.7) | 9.8 (9.6, 10.0) | 9.3 (8.9, 9.6) | 6.4 (6.0, 6.7) | 13.6 (13.0, 14.2) |
| 40–54 | 26.0 (25.9, 26.1) | 23.6 (23.3, 23.8) | 21.6 (21.1, 22.1) | 21.8 (21.2, 22.3) | 32.3 (31.5, 33.2) |
| 55–64 | 16.0 (15.9, 16.1) | 25.6 (25.3, 25.9) | 24.3 (23.8, 24.8) | 26.7 (26.1, 27.4) | 27.9 (27.1, 28.7) |
| 65–74 | 10.9 (10.8, 11.0) | 23.2 (22.9, 23.5) | 25.3 (24.7, 25.8) | 25.8 (25.2, 26.4) | 17.0 (16.3, 17.7) |
| 75–84 | 5.9 (5.8, 5.9) | 13.2 (12.9, 13.4) | 14.6 (14.2, 15.1) | 14.6 (14.1, 15.1) | 7.1 (6.6, 7.5) |
| ≥85 | 2.6 (2.6, 2.7) | 4.7 (4.5, 4.8) | 4.9 (4.7, 5.2) | 4.8 (4.5, 5.1) | 2.1 (1.8, 2.4) |
| Sex | |||||
| Female | 54.2 (54.1, 54.3) | 49.9 (49.5, 50.2) | 52.6 (51.9, 53.2) | 48.4 (47.7, 49.1) | 48.2 (47.3, 49.1) |
| Male | 45.7 (45.6, 45.9) | 50.1 (49.8, 50.5) | 47.4 (46.8, 48.1) | 51.6 (50.9, 52.3) | 51.8 (50.9, 52.7) |
| Hispanic ethnicityb | |||||
| Yes | 18.4 (18.3, 18.5) | 21.5 (21.2, 21.7) | 17.7 (17.2, 18.2) | 21.5 (20.9, 22.0) | 29.5 (28.7, 30.3) |
| No | 71.2 (71.1, 71.4) | 74.3 (74.0, 74.6) | 79.1 (78.6, 79.6) | 74.8 (74.2, 75.4) | 66.6 (65.7, 67.4) |
| Raceb | |||||
| Asian | 2.8 (2.8, 2.9) | 3.2 (3.1, 3.3) | 3.2 (2.9, 3.4) | 3.3 (3.1, 3.6) | 2.4 (2.1, 2.6) |
| Black | 14.6 (14.5, 14.7) | 24.0 (23.7, 24.2) | 23.4 (22.9, 24.0) | 21.0 (20.4, 21.5) | 28.6 (27.8, 29.4) |
| White | 61.8 (61.6, 61.9) | 54.6 (54.2, 54.9) | 59.2 (58.6, 59.8) | 59.1 (58.4, 59.8) | 46 (45.1, 46.8) |
| Otherc | 11.1 (11.1, 11.2) | 13.1 (12.8, 13.3) | 9.8 (9.5, 10.2) | 11.3 (10.9, 11.8) | 16.4 (15.8, 17.1) |
| BMIb kg/m2 | |||||
| <18.5 | 1.6 (1.6, 1.7) | 1.5 (1.4, 1.5) | 1.4 (1.2, 1.5) | 1.3 (1.1, 1.4) | 1.5 (1.3, 1.8) |
| 18.5 to <25 | 21.9 (21.8, 22.0) | 13.9 (13.7, 14.1) | 14.1 (13.7, 14.6) | 11.0 (10.6, 11.5) | 12.9 (12.3, 13.5) |
| 25 to <30 | 30.1 (30.0, 30.3) | 25.7 (25.4, 26.0) | 25.1 (24.5, 25.6) | 25.5 (24.9, 26.1) | 24.3 (23.5, 25.1) |
| 30 to <35 | 22.8 (22.7, 22.9) | 25.1 (24.8, 25.4) | 25.3 (24.8, 25.8) | 26.4 (25.8, 27.0) | 25.3 (24.6, 26.1) |
| 35 to <40 | 12.5 (12.4, 12.6) | 16.6 (16.4, 16.9) | 16.5 (16.0, 16.9) | 18.0 (17.4, 18.5) | 17.3 (16.6, 17.9) |
| ≥40 | 11.0 (10.9, 11.1) | 17.3 (17.0, 17.5) | 17.6 (17.2, 18.1) | 17.9 (17.3, 18.4) | 18.7 (18.0, 19.4) |
| COVID-19 medications | |||||
| Dexamethasone | 6.4 (6.3, 6.4) | 16.5 (16.3, 16.8) | 15.2 (14.8, 15.7) | 15.5 (15.0, 16.0) | 15.7 (15.1, 16.4) |
| Other corticosteroids | 5.4 (5.3, 5.4) | 12.6 (12.4, 12.8) | 13.6 (13.2, 14.0) | 11.9 (11.4, 12.3) | 10.8 (10.3, 11.4) |
| Remdesivir | 4.6 (4.5, 4.6) | 13.8 (13.5, 14) | 12.7 (12.3, 13.1) | 14.1 (13.6, 14.5) | 14.6 (14.0, 15.2) |
a
Includes 27,981 who met the criteria for diabetes but could not be classified by control status (i.e., did not have HbA1c measurement within 18 months before COVID-19).
b
Missing data not shown.
c
Other includes PCORnet values of Native Hawaiian or other Pacific Islander, American Indian or Alaska Native, multiple race, and other.
DM, diabetes mellitus; PCORnet, National Patient-Centered Clinical Research Network.